Non-obese visceral adiposity is associated with the risk of atherosclerosis in Japanese patients with rheumatoid arthritis: a cross-sectional study

Tamami Yoshida1 · Motomu Hashimoto2 · Rie Kawahara1 · Hiroko Yamamoto1 · Masao Tanaka2 · Hiromu Ito3 · Izuru Masuda4 · Kiminori Hosoda5 · Wataru Yamamoto2 · Ryuji Uozumi6 · Satoshi Morita6 · Yasutomo Fujii1 · Tsuneyo Mimori7 · Kazuko Nin1

Received: 27 April 2018 / Accepted: 25 June 2018 / Published online: 4 July 2018
© The Author(s) 2018

Abstract
Rheumatoid arthritis (RA) patients often have altered body composition including reduced muscle mass and increased fat mass. Some RA patients are likely to increase visceral fat without obesity [Body Mass Index (BMI) ≥ 25]. The objective of the study was to determine the association between obesity and/or visceral adiposity and the risk for atherosclerosis in Japanese RA patients. Obesity was evaluated using the BMI, with visceral adiposity evaluated using the visceral fat area (VFA) and the visceral/subcutaneous fat ratio (V/S ratio), quantified using the dual bioelectrical impedance method. Atherosclerosis was evaluated based on the intima–media thickness (IMT) and Plaque score (PS) of the carotid artery, measured using ultrasonography. Multivariate analysis was performed to determine the factors associated with IMT and PS. IMT and PS were compared among groups of patients sub-classified according to BMI and VFA levels. The V/S ratio was higher in RA patients than healthy controls, after adjustment for age, BMI, and waist circumference. On multivariate analysis, the V/S ratio, but not the BMI, was independently associated with the IMT and PS. Among the sub-classifications for BMI and VFA, non-obese patients with a high visceral adiposity (18.5 ≤ BMI < 25 kg/m² and VFA ≥ 100 cm²) had the highest IMT (mean IMT, 0.93 ± 0.29 mm; maximum IMT, 1.44 ± 0.71 mm) and PS (1.43 ± 0.61), compared to all other BMI and VFA subgroups. RA patients have increased visceral adiposity, which is associated with a high prevalence of atherosclerotic plaques. Non-obese RA patients who have visceral adiposity have a specifically higher risk for atherosclerosis.

Keywords Rheumatoid arthritis · Atherosclerosis · Intra-abdominal fat · Adiposity · Cachexia

Introduction
Patients with rheumatoid arthritis (RA) have a decreased life expectancy compared to the general population due to RA-related health complications and long-term comorbidities [1, 2]. Among these complications, cardiovascular diseases (CVD) are specifically important due to their prevalence among patients with RA and their association with a high mortality rate [3–5]. Atherosclerosis plays an importance role in the development of CVD, with both traditional risk factors (smoking, dyslipidemia, hypertension, physical inactivity, and obesity) and RA-related factors (disease activity and duration) synergistically contributing to the development of atherosclerosis in patients with RA [6].

Obesity is a well-known risk factor of atherosclerosis, with the Body Mass Index (BMI) being a well-established risk factor for CVD [7]. However, CVD in patients with RA is not necessarily associated with obesity, with a low BMI having been associated with CVD events and increased mortality among these patients [8, 9]. Of note is the tendency of patients with a low BMI to have higher disease activity and a worse joint prognosis than patients with a higher BMI [9]. This discrepancy is known as the “obesity paradox”.

One of the reasons for this “obesity paradox” may be a change in body composition due to chronic inflammation in patients with RA. Patients with RA also often develop “rheumatoid cachexia”, defined as a reduction in muscle
mass and a concomitant increase in fat mass [10–12]. However, it is not clear whether subcutaneous or visceral fat mass is increased in rheumatoid cachexia [13]. This is an important distinction as an excess accumulation of visceral fat is associated with metabolic abnormalities, such as hypertension, diabetes, and dyslipidemia, which accelerate atherosclerosis and CVD [14, 15]. It is possible that patients with RA who are initially obese may lose weight due to chronic inflammation, achieving a normal BMI despite an increase in visceral fat mass, with an overall increased risk for atherosclerosis. Based on this reasoning, we hypothesized that measurement of the visceral fat mass might better differentiate patients with RA who are at risk for atherosclerosis than the BMI.

To test this hypothesis, we evaluated the association between body composition [BMI, the visceral fat area (VFA) and the visceral-to-subcutaneous fat ratio (V/S ratio)] and atherosclerosis in patients with RA, where the VFA and V/S ratios were quantified using dual biometrical impedance and atherosclerosis using the intima–media thickness (IMT) and Plaque score (PS) of the common carotid artery (CCA), measured with ultrasonography [16, 17]. Traditional atherosclerosis-related factors and RA-related factors were also evaluated and their association to obesity and visceral adiposity tested.

**Methods**

This study was a cross-sectional observational study. It adhered to the principles of the Declaration of Helsinki and was approved by the ethics committee of Kyoto University Graduate School and Faculty of Medicine. Approval number: R-357 for RA patients (24 March 2016) and R-0588 for the healthy control group (13 September 2016); informed consent was obtained from all participants.

**Patient study group**

We recruited 441 consecutive outpatients with RA from the Kyoto University Rheumatoid Arthritis Management Alliance (KURAMA), between May 1 and November 30, 2016. The inclusion criteria were as follows: age > 18 years; availability of a complete data set; and fulfillment of the American College of Rheumatology/European League against Rheumatism classification 2010 criteria for RA [18]. The following exclusion criteria were applied: presence of an internal or external electronic device; severely degraded health status; presence of fractures and pain preventing assessment of visceral and subcutaneous fat; waist circumference (WC) < 57 cm; poor physical health on the day of examination, defined by the patient’s subjective symptoms; and concurrent cancer and hepatitis treatment, dialysis, and/or sex-hormone suppression or replacement therapy.

**Healthy control group**

As a control group, we used the existing data of 1527 of 2085 healthy subjects who underwent a comprehensive medical checkup at Takeda Hospital Medical Examination Center and had complete VFA data available. To be included, patients had to be > 18 years and have a complete data set. The exclusion criteria were as follows: prior or current history of cancer, hepatitis, or dialysis; disease affecting dietary intake; inflammatory, wasting, and/or autoimmune disease; use of steroids and/or sex-hormone suppression or replacement therapy. The patients had provided consent for the use of their anonymized data for research.

**Assessment of atherosclerosis**

The IMT and PS for the CCA were evaluated by high-resolution B-mode ultrasonography (Aplio300,500, Toshiba Inc., Japan) using a 12-MHz transducer. The CCA-IMT was measured bilaterally, with patients in the sitting position, 1 cm proximal to the carotid bulb dilatation, with measurements obtained for the far wall of the CCA using an IMT measurement software (Intimascope, Media Cross Co Ltd., Japan) [19]. Plaques were defined as localized elevated lesions with a maximum thickness of more than 1 mm, having a point of inflection on the surface of the intima–media complex. In cases of vascular remodeling, the term plaques was used, irrespective of the presence/absence [20]. For analysis, we used the average IMT of the measurements obtained for the right and left CCA, with plaques included when measuring IMT. The PS was calculated as the total plaque thickness for the available visualization sites in the IMT measurement on the right and left sides.

**Assessment of body composition**

Height, weight, WC, and the skeletal muscle ratio (SMR) were measured using standardized protocols. The BMI was calculated as the weight divided the height squared (kg/m²). The SMR was measured using a Z impedance analyzer (HBF-701 KARADASCAN, Omron Healthcare Co., Japan) with hand grip and foot plate electrodes [21]. The VFA and subcutaneous fat area (SFA) were measured using a dual bioelectrical impedance analyzer (HDS-2000 DUALSCAN, Omron Healthcare Co., Japan).
The previous studies have demonstrated a high correlation coefficient \((r = 0.888, p < 0.001)\) between VFA measured by a dual bioelectrical impedance analyzer and that measured by abdominal computed tomography (CT) [22].

**Body composition phenotype**

According to the definition of obesity and visceral fat in Japan [23], we used a cut-off BMI of 25 kg/m\(^2\) for obesity and a VFA of 100 cm\(^2\) for visceral fat. RA patients were classified into five groups as follows: Thinness (+), BMI < 18.5 and VFA < 100; Obesity (−) Visceral adiposity (−), 18.5 ≤ BMI < 25 and VFA < 100; Obesity (−) Visceral adiposity (+), 18.5 ≤ BMI < 25 and VFA ≥ 100; Obesity (+) Visceral adiposity (−), BMI ≥ 25 and VFA < 100; and Obesity (+) Visceral adiposity (+), BMI ≥ 25 and VFA ≥ 100.

**Traditional risk factors for atherosclerosis**

The following sociodemographic and lifestyle variables were included in the analysis: age, sex, smoking (current smoker or non-smoker), alcohol intake per week, statin use, family history of premature myocardial infarction (< 65 years), and physical activity level, evaluated using the short version of the International Physical Activity [24]. Hypertension was defined as systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg, measured with a blood pressure monitor after a few minutes of resting in a sitting position, or the use of antihypertensive medication. Diabetes was defined as an HbA1c > 6.5% or use of antidiabetic medication. Dyslipidemia was defined as a low-density lipoprotein (LDL-C) ≥ 140 mg/dL or use of statins. The following laboratory variables were included in the analysis: total cholesterol (TC), triglycerides (TG), LDL-C, high-density lipoprotein (HDL-C), and estimated glomerular filtration rate (eGFR).

**RA-related factors**

RA disease activity was evaluated using the 28-Joint RA Disease Activity Score (DAS28-ESR) and RA-related physical disability was evaluated using the health assessment questionnaire-disability index (HAQ). Disease status was evaluated using the following laboratory variables: rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP antibodies), matrix metalloproteinase-3 (MMP-3), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). RA treatment included methotrexate (MTX, dosage per week) and the use of biological disease modifying anti-rheumatoid disease drugs (bDMARD) and prednisolone (dosage per day).

**Statistical analysis**

Variables with a normal distribution were expressed by their mean ± standard deviation, with variables with a non-normal distribution summarized by their median and range. Comparisons between the RA and control group were performed using \(t\) tests for continuous variables and Chi-squared test for categorical variables. Propensity score matching was performed to ensure rigorous adjustment for the comparison of fat-related variables. A 1:1 matching ratio was created using the neighbor pair-matching algorithm, with a 0.2 caliper width, adjusting for age, BMI, and WC, by sex. Visceral fat-related variables were compared between the RA and control groups after matching by sex.

The relationship between VFA or BMI and hypertension, diabetes, and dyslipidemia was evaluated for the five levels of VFA and three levels of BMI. Odds ratios (ORs), with the corresponding 95% confidence intervals (CIs), were calculated using logistic regression analysis, with adjustment for the covariates of age, sex, current smoking (+), average daily physical active level, alcohol intake per week, use of bDMARDs, prednisolone and MTX, and the DAS28-ESR score.

An analysis of covariance (ANCOVA) was used to evaluate the effect of each predictor on the mean CCA-IMT and PS. Forward stepwise multivariate analyses were performed to identify the effect of predictors in the presence of other factors associated with the mean CCA-IMT and PS. RA-related variables and metabolic risk factors with a \(p\) value < 0.05 in the univariate analyses were included in the multivariate analyses. The relationship between atherosclerotic indicators and body composition (BC) phenotype was evaluated using a one-way analysis of variance for continuous variables and Fisher’s exact test for categorical variables, with a Steel–Dwass post-hoc test for multiple comparisons.

For all analyses, a \(p\) value < 0.05 was considered significant. All statistical analyses were performed using JMP (version 11, SAS Institute Inc., Cary, NC, USA).

**Results**

**Characteristics of RA patients**

All 441 consecutive patients enrolled into the study underwent BC measurement and CCA ultrasonography on the same day, together with the evaluation of traditional risk factors for atherosclerosis (diabetes, hypertension, and dyslipidemia, etc.) and RA-related factors (disease activity, etc.). After screening on the exclusion criteria (Fig. 1), the data of 352 patients (292 women, 60 men) were retained for...
analysis, with an average age of 61.8 years and average RA disease duration of 7 years (Table 1). As MTX, bDMARDs, and prednisolone were used by 72.4, 52.0, and 21.0% of patients, respectively, the mean RA disease activity (DAS28-ESR) was generally low (2.52), with 75.0% of patients being either remission or having low disease activity.

**Comparison of body composition between the RA and control group**

BC was compared between the RA and the control group, with adjustment for age, BMI, and WC (Table 2). After matching, 285 individuals from each group were included in the analysis (226 women and 59 men). Overall, there was no between-group difference in VFA. However, the proportion of females in the highest VFA classification (VFA ≥ 100 cm²) was higher in the RA than control group (8.4 versus 3.1%, respectively; \( p = 0.015 \)). The V/S ratio was higher in the RA than control group, even after adjustment for BMI and WC, for both females (0.39 ± 0.18 versus 0.34 ± 0.13; \( p = 0.002 \)) and males (0.58 ± 0.16 versus 0.51 ± 0.13; \( p = 0.013 \)). This result suggests that the visceral fat mass distribution was higher for the RA than control group.

**Association between obesity and visceral adiposity with traditional risk factors for atherosclerosis**

The association between obesity and visceral adiposity with traditional risk factors of atherosclerosis (hypertension, diabetes, and dyslipidemia) was evaluated for the 352 patients in the RA group across the 3 BMI levels (BMI-1; BMI < 18.5, BMI-2: 18.5 ≤ BMI < 25, and BMI-3; BMI ≥ 25) and 5 visceral adiposity levels (VFA-1; VFA < 25, VFA-2; 25 ≤ VFA < 50, VFA-3; 50 ≤ VFA < 75, VFA-4; 75 ≤ VFA < 100, and VFA-5; VFA ≥ 100). With regard to BMI, the incidence of hypertension and dyslipidemia was higher in the BMI-3 than either BMI-1 or BMI-2 levels (Table 3). Similarly, the incidence of hypertension, diabetes, and hyperlipidemia was higher in the VFA-5 level than any other of the 4 VFA levels (VFA-1 through VFA4; Table 3). The CCA-IMT and PS also increased with the degree of obesity and adiposity (Table 3). This result suggests that both obesity and visceral adiposity are associated with traditional risk factors of atherosclerosis, with patients in the highest BMI (BMI ≥ 25) and VFA (VFA ≥ 100) levels being at highest risk of atherosclerosis.

**Factors associated with atherosclerosis in patients with RA**

The association between obesity and visceral adiposity and CCA-IMT and PS is presented in Table 4. On univariate analysis, CCA-IMT was positively associated with traditional risk factors for atherosclerosis, including SBP, TC, LDL-C, diabetes, BMI, and visceral adiposity (VFA, V/S ratio) while negatively associated with eGFR and HDL-C. On multivariate analysis, the V/S ratio, but not BMI, was independently associated with CCA-IMT (Table 4). Similarly, PS was also positively associated with traditional risk factors for atherosclerosis, including current smoking and visceral adiposity (VFA, V/S ratio) while negatively associated with HDL-C. In addition to the traditional risk factors, RA-related factors, including disease activity (DAS-ESR), MMP-3, and the use of glucocorticoids were also positively associated with PS. On multivariate analysis, sex (male),
the V/S ratio and the DAS28-ESR score were independently associated with PS. This result suggests that visceral adiposity (V/S ratio) is a stronger indicator of atherosclerosis than obesity (BMI) in patients with RA.

No significant associations were observed between the atherosclerotic indicators (CCA-IMT and PS) and the SFA, diastolic blood pressure, physical active level, family history of CVD, RA disease duration, RF, anti-CCP, CRP, use of specific bDMARDs (TNF inhibitor), MTX dosage, or statin therapy.

### Relationship between body composition phenotype and the risk of atherosclerosis

The CCA-IMT and PS and risk factors for atherosclerosis were evaluated across the five classifications of BC phenotype (Table 5). Both CCA-mean IMT and PS were remarkably higher in the Obesity (−) Visceral adiposity (+) group (mean ± SD, 0.93 ± 0.29 for CCA-mean IMT and 1.43 ± 0.61 for PS). The CCA-IMT and PS were similar among the other groups, including the Obesity (+) Visceral adiposity (+) and Thinness (+) groups. Notably, RA disease activity was higher in the Thinness (+) group (mean ± SD, 3.24 ± 1.03) than any other group ($p$ = 0.047).

Therefore, non-obese patients with RA who have visceral adiposity are specifically at high risk for atherosclerosis, with patients in the Thinness (+) group having higher disease activity than patients in the normal and obese groups.

### Discussion

Our evaluation of the association between obesity and visceral adiposity and risk of atherosclerosis in patients with RA revealed a higher VFA in patients with RA than a healthy control group, with the visceral adiposity being an independent predictor of atherosclerosis in these patients. Moreover, we identified a specific risk for atherosclerosis among non-obese patients with RA patients having high visceral adiposity. Although the association between obesity, adiposity, and the risk of atherosclerosis has previously been evaluated [25, 26], our study is the first to have evaluated BC...
and atherosclerosis simultaneously in a cohort of patients with RA patients, including potential atherosclerosis-related and RA-related confounding factors.

Our finding of an increase in visceral fat mass in the RA group compared to the control group is consistent with the previous reports of a higher VFA or trunk fat in patients with RA than a control group [25, 26]. Although a WC ≥ 85 cm in females and 90 cm in males is generally used to screen for increased visceral fat mass in Japanese patients based on the definition of obesity and visceral fat obesity in Japan [23]. This is different from the cut-off value in Europe (80 cm for females and 94 cm for males) and in the United States (88 cm for females and 102 cm for males). Our findings indicate that WC might not be sufficient as it is the V/S ratio which was specifically increased between the RA and control group, even after adjustment for BMI and WC. Therefore, measurement of the visceral fat mass (VFA or V/S ratio) may be more suitable to differentiate patients at risk for atherosclerosis and CVD events than the BMI. In fact, on multivariate analysis, the V/S ratio but not BMI remained as an independent factor associated with atherosclerosis in the RA group. Of note, patients with a normal BMI but a VFA ≥ 100 cm² (Obesity (−), Visceral adiposity (+) group) had particularly high CCA-IMT and PS compared to the other groups. Adipose tissue produces and secretes biologically active substances, collectively called adipocytokines, which include both pro-atherosclerotic and anti-atherosclerotic substances [27]. The dysregulation of adipocytokines may contribute to the pathogenesis of atherosclerosis in patients with a higher V/S fat ratio [28].

Our result is conceptually consistent that patients with RA have a unique body composition, called “rheumatoid cachexia”. In general, “cachexia” is a complex metabolic syndrome associated with underlining illness and characterized by loss of body weight and loss of muscle mass and fat mass [29]. In contrast, in RA, muscle wasting is a common feature, but the fat mass is preserved, or even increased, such that a low BMI is uncommon in these patients. Therefore, two types of cachexia appear to exist among patients with RA [13], namely, “classical cachexia”, characterized by a low BMI and low VFA (Thinness (+) group in our study), and “rheumatoid cachexia”, characterized by a normal BMI with increased adipose tissue [Obesity (−) Visceral adiposity (+) group in our study]. The latter might also be called for “sarcopenic obesity” [30, 31] or “visceral fat obesity”.

In our study, patients with “classical cachexia” [Thinness

Table 2  Comparison of visceral fat-related variables between patients with RA and the control group, before and after propensity score matching

| Sex     | Variables | Before matching | After matching* |
|---------|-----------|----------------|----------------|
|         | RA patients | Controls | p value† | RA patients | Controls | p value† |
| Women   | n          | 292     | 482     | 226     | 226     |
| Age, years | 61.4 ± 12.2 | 53.9 ± 11.7 | < 0.001 | 58.7 ± 11.8 | 58.7 ± 11.8 | 0.959 |
| Body Mass Index, kg/m² | 22.3 ± 3.7 | 23.0 ± 3.4 | 0.012 | 22.6 ± 3.8 | 22.6 ± 3.0 | 0.925 |
| WC, cm | 83.3 ± 10.2 | 82.0 ± 9.1 | 0.074 | 82.9 ± 0.6 | 82.9 ± 0.6 | 0.976 |
| VFA, cm² | 56.0 ± 28.1 | 53.1 ± 27.0 | 0.145 | 55.3 ± 29.0 | 53.8 ± 23.7 | 0.538 |
| V/S ratio | 0.40 ± 0.18 | 0.33 ± 0.15 | < 0.001 | 0.39 ± 0.18 | 0.34 ± 0.13 | 0.002 |
| VFA ≥ 100 cm², n (%) | 25 (8.6) | 23 (4.8) | 0.034 | 19 (8.4) | 7 (3.1) | 0.015 |
| SFA, cm² | 152.5 ± 72.9 | 173.1 ± 70.4 | < 0.001 | 156.3 ± 75.2 | 168.6 ± 65.9 | 0.064 |
| Man     | n          | 60     | 1045    | 59     | 59     |
| Age, years | 63.8 ± 10.6 | 52.7 ± 10.9 | < 0.001 | 64.5 ± 9.1 | 64.3 ± 9.4 | 0.905 |
| Body Mass Index | 24.2 ± 3.2 | 24.2 ± 2.9 | 0.998 | 24.3 ± 3.0 | 24.7 ± 3.2 | 0.481 |
| WC, cm | 88.1 ± 1.0 | 86.3 ± 0.3 | 0.084 | 88.6 ± 8.4 | 89.7 ± 7.6 | 0.459 |
| VFA, cm² | 90.3 ± 37.5 | 79.0 ± 34.5 | 0.015 | 91.7 ± 36.4 | 89.8 ± 35.0 | 0.778 |
| V/S ratio | 0.57 ± 0.17 | 0.48 ± 0.16 | < 0.001 | 0.58 ± 0.16 | 0.51 ± 0.13 | 0.013 |
| VFA ≥ 100 cm², n (%) | 23 (38.3) | 232 (22.2) | 0.004 | 23 (39.0) | 22 (37.3) | 0.850 |
| SFA, cm² | 158.2 ± 53.9 | 163.1 ± 53.9 | 0.450 | 159.7 ± 53.1 | 174.4 ± 54.5 | 0.139 |

Values are shown as mean ± SD or number (percentage)

WC waist circumference, VFA visceral fat area, V/S visceral fat area/subcutaneous area, SFA subcutaneous fat area

*The matching ratio is 1:1 with adjusting for age, Body Mass Index and waist circumference

† t test for continuous variables and Chi-squared test for categorical variables
(+) show higher disease activity, while the patients with “rheumatoid cachexia” [Obesity (−) Visceral adiposity (+)] show high risk of atherosclerosis. Because patients with RA may lose body weight due to chronic inflammation [32], our Obesity (−) Visceral adiposity (+) group might include patients who were initially obese, and, therefore, at high risk for atherosclerosis, and lost weight due to chronic inflammation. However, these speculations will need to be carefully evaluated through longitudinal studies in the future.

Whereas “classical cachexia” can be easily diagnosed by a low BMI, “rheumatoid cachexia” with normal BMI and increased visceral fat mass is difficult to detect by routine clinical examination, with WC being an insufficient measure. Measurement of the VFA and V/S ratio by bioelectrical impedance method may be useful to identify patients at real risk for atherosclerosis and CVD events. The European League against Rheumatism for CVD risk management among patients with RA recommended assessment of both traditional CVD risk factors and RA-specific factors [33] and screening for asymptomatic atherosclerotic plaques by use of carotid ultrasound as part of the CVD risk evaluation [34]. We propose that the evaluation of visceral fat is important to improve the management of atherosclerosis and CVD in patient with RA.

Limitations of our study include the use of bioelectrical impedance, rather than the gold standard abdominal CT, for the measurement of the VFA and V/S ratios, to lower the exposure to ionized radiation and recruitment of patients from a single institution, increasing the risk for selection bias and the inclusion of only Japanese individuals, who are generally thinner and with a lower risk for CVD event compared to Europeans (based on the Organization for Economic Co-operation and Development’s data). Of note, elderly patients with RA, who tend to have more joint symptoms, were not included in our study, which would limit the generalization of our findings. Despite these limitations, we consider that our findings adequately reflect the patients with RA in a typical clinical practice.

In conclusion, the accumulation of visceral fat along with a normal BMI was associated with a high prevalence of atherosclerotic plaques in patients with RA. Therefore, evaluation of the VFA may be useful for assessing CVD risk in these patients. Effective management of the risk for atherosclerosis and CVD events to improve life expectancy of patients with RA is important as advances of RA therapies are improving the control over disease activity and joint outcomes. Precise identification would improve this risk management.

| Table 3 | Multivariate analyses for metabolic syndrome-related disease by each stage of VFA and BMI |
|---------|-----------------------------------------------------------------------------------------|
| N=352  | Hypertension (n=113)                                                                   |
|         | Diabetes (n=113)                                                                         |
| OR      | VFA stage                                                                               |
| OR      | BMI stage                                                                               |
| p-value | OR                                      | Lower CI | Upper CI | p-value | Lower CI | Upper CI | p-value | Lower CI | Upper CI | p-value | Lower CI | Upper CI | p-value |
| N=352  |                                                                                       |          |          | OR      |          |          |         |          |          | OR      |          |          |         | OR      |          |          |         |          |          |         |
| VFA-1  | 1.00 Reference                                                                         | 1.00     | Reference | 1.00 | OR 0.36 | 0.28 | 1.36 | 0.003 | OR 5.56 | 0.32 | 1.08 | 0.02 | OR 108.02 | 0.003 | OR 108.02 | 0.003 | OR 108.02 | 0.003 | OR 108.02 | 0.003 |
| VFA-2  | 1.00 Reference                                                                         | 1.00     | Reference | 1.00 | OR 0.36 | 0.28 | 1.36 | 0.003 | OR 5.56 | 0.32 | 1.08 | 0.02 | OR 108.02 | 0.003 | OR 108.02 | 0.003 | OR 108.02 | 0.003 | OR 108.02 | 0.003 |
| VFA-3  | 1.00 Reference                                                                         | 1.00     | Reference | 1.00 | OR 0.36 | 0.28 | 1.36 | 0.003 | OR 5.56 | 0.32 | 1.08 | 0.02 | OR 108.02 | 0.003 | OR 108.02 | 0.003 | OR 108.02 | 0.003 | OR 108.02 | 0.003 |
| VFA-4  | 1.00 Reference                                                                         | 1.00     | Reference | 1.00 | OR 0.36 | 0.28 | 1.36 | 0.003 | OR 5.56 | 0.32 | 1.08 | 0.02 | OR 108.02 | 0.003 | OR 108.02 | 0.003 | OR 108.02 | 0.003 | OR 108.02 | 0.003 |
| VFA-5  | 1.00 Reference                                                                         | 1.00     | Reference | 1.00 | OR 0.36 | 0.28 | 1.36 | 0.003 | OR 5.56 | 0.32 | 1.08 | 0.02 | OR 108.02 | 0.003 | OR 108.02 | 0.003 | OR 108.02 | 0.003 | OR 108.02 | 0.003 | OR 108.02 | 0.003 |

Covariates: age, sex, current smoking (+), average daily physical activity level, alcohol intake per week, biologicals use, prednisolone use, methotrexate use, and DAS28-ESR

BMI: Body Mass Index
Table 4  Univariate and multivariate analyses for independent factors associated with the mean IMT and Plaque score in patients with RA

| Dependent variable | Independent variables | Univariate | Multivariate |
|--------------------|-----------------------|------------|-------------|
|                    |                      | $\beta$    | 95% CI       | $p$         | $\beta$    | 95% CI       | $p$         | Standardized $\beta$ |
| Mean IMT           | Age (10 years)       | 0.073      | 0.062 to 0.085 | <0.001      | 0.063      | 0.051–0.075  | <0.001      | 0.474       |
|                    | Sex (male)           | 0.081      | 0.038 to 0.124 | <0.001      | 0.050      | 0.012–0.088  | 0.01        | 0.119       |
|                    | Body Mass Index (1 unit) | 0.006 | 0.002 to 0.012 | 0.009      |           |             |             |             |
|                    | WC (cm)              | 0.003      | 0.001 to 0.004 | 0.001      |           |             |             |             |
|                    | VFA (10 cm²)         | 0.011      | 0.006 to 0.016 | <0.001      |           |             |             |             |
|                    | V/S ratio (per 0.1)  | 0.016      | 0.007 to 0.025 | <0.001      | 0.008      | <0.001–0.016 | 0.037       | 0.096       |
|                    | Systemic SMR (%)     | −0.008     | −0.013 to −0.003 | 0.002      |           |             |             |             |
|                    | Systolic BP (10 mmHg) | 0.028 | 0.018 to 0.037 | <0.001      | 0.009      | <0.001–0.018 | 0.032       | 0.100       |
|                    | eGFR (mL/min/1.73 m²) | −0.002 | −0.003 to −0.001 | <0.001      |           |             |             |             |
|                    | TC (10 mg/dL)        | 0.008      | 0.003 to 0.013 | 0.001      |           |             |             |             |
|                    | LDL-C (10 mg/dL)     | 0.012      | 0.007 – 0.019   | <0.001      | 0.007      | 0.002–0.012  | 0.004       | 0.130       |
|                    | HDL-C (10 mg/dL)     | −0.010     | −0.018 to −<0.001 | 0.038      |           |             |             |             |
|                    | Triglycerides (10 mg/dL) | 0.006 | 0.003 to 0.010 | <0.001      |           |             |             |             |
|                    | Diabetes (+)         | 0.101      | 0.041 to 0.160 | 0.001      |           |             |             |             |
| Plaque score       | Age (10 years)       | 0.090      | <0.001 to 0.171 | 0.049      |           |             |             |             |
|                    | Sex (male)           | 0.543      | 0.277 to 0.809  | <0.001      | 0.489      | 0.208–0.770  | <0.001      | 0.189       |
|                    | VFA (10 cm²)         | 0.050      | 0.018 to 0.081  | 0.002      |           |             |             |             |
|                    | V/S ratio (per 0.1)  | 0.089      | 0.036 to 0.142 | 0.001      | 0.057      | 0.002–0.112  | 0.043       | 0.111       |
|                    | Systemic SMR (%)     | 0.034      | 0.003 to 0.066 | 0.033      |           |             |             |             |
|                    | HDL-C (10 mg/dL)     | −0.066     | −0.121 to −0.012 | 0.017      |           |             |             |             |
|                    | Current smoking (+)  | 0.478      | 0.110 to 0.847  | 0.011      |           |             |             |             |
|                    | DAS28-ESR (1 unit)   | 0.108      | 0.001 to 0.216  | 0.049      | 0.133      | 0.028–0.238  | 0.014       | 0.129       |
|                    | MMP-3 (10 ng/mL)     | 0.010      | 0.002 to 0.023 | 0.025      |           |             |             |             |
|                    | PSL dosage (mg/dL/day) | 0.067 | 0.014 to 0.120 | 0.013      |           |             |             |             |

$N=352$. Units in parentheses are units for $\beta$ as estimated values

Independent variables (in mean IMT and Plaque score): RA-related variables and metabolic risk factors with a $p$ value < 0.05 in the univariate analyses are described

Covariate in multivariate analyses: covariates are variables in which numerical values are listed. These covariates were selected using a stepwise method use $p < 0.05$ for (rather than in) independent variables

CI confidence interval, standardized $\beta$ standardized partial regression coefficient, VIF variance inflation factor, WC waist circumference, VFA visceral fat area, V/S visceral fat area/subcutaneous area, SMR skeletal muscle ratio, BP blood pressure, eGFR estimated glomerular filtration rate, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, DAS28-ESR 28-joint Disease Activity Score using erythrocyte sedimentation rate, MMP-3 matrix metalloproteinase-3, PSL prednisolone.
### Table 5  Characteristics of RA patients according to body composition phenotype combined with VFA and BMI

| N=352 | BMI < 18.5 | 18.5 ≤ BMI < 25 | BMI ≥ 25 | p value* |
|-------|------------|-----------------|----------|----------|
|       | VFA < 100  | VFA < 100       | VFA ≥ 100| VFA ≥ 100|
|        | Obesity (−) Visceral adiposity (−) n=224 (63.6%) | Obesity (−) Visceral adiposity (−) n=12 (3.4%) | Obesity (+) Visceral adiposity (+) n=45 (12.8%) | Obesity (+) Visceral adiposity (+) n=34 (9.7%) |
| Age (years) | 61.3 ± 13.3 | 61.1 ± 12.1 | 71.8 ± 6.7 | 62.1 ± 11.7 | 62.3 ± 9.6 | 0.054 |
| Male, n (%) | 1 (2.7) | 31 (13.8) | 7 (58.3) | 6 (13.3) | 15 (20.6) | 0.002 |
| Mean IMT (mm) | 0.67 ± 0.12 | 0.68 ± 0.15 | **0.93 ± 0.29** | 0.73 ± 0.16 | 0.72 ± 0.11 | < 0.001 |
| Max IMT (mm) | 0.85 ± 0.17 | 0.88 ± 0.32 | **1.44 ± 0.71** | 0.97 ± 0.30 | 0.91 ± 0.17 | < 0.001 |
| Max IMT 1.0 mm or more, n (%) | 7 (18.9) | 46 (20.5) | 10 (83.3) | 11 (24.4) | 9 (26.5) | < 0.001 |
| Plaque score | 0.0 (0) | 0.13 ± 0.04 | **1.43 ± 0.61** | 0.38 ± 0.26 | 0.28 ± 0.19 | < 0.001 |
| Body composition indicators | | | | | |
| VFA (cm²) | 33.7 ± 15.0 | 50.6 ± 19.1 | 113.8 ± 13.6 | 78.2 ± 15.8 | 126.8 ± 26.6 | < 0.001 |
| SFA (cm²) | 69.6 ± 25.7 | 137.7 ± 48.0 | 156.9 ± 39.8 | 228.4 ± 57.3 | 247.8 ± 66.7 | < 0.001 |
| V/S ratio | 0.50 ± 0.22 | 0.40 ± 0.17 | **0.76 ± 0.16** | 0.36 ± 0.13 | 0.54 ± 0.17 | < 0.001 |
| Waist circumference (cm) | | | | | |
| Man | 63.0 ± 0 | 83.4 ± 6.0 | 87.9 ± 3.9 | 92.3 ± 7.0 | 98.0 ± 5.7 | < 0.001 |
| Women | 71.2 ± 5.1 | 81.5 ± 7.3 | 92.4 ± 4.5 | 94.0 ± 7.1 | 100.5 ± 6.8 | < 0.001 |
| Systemic skeletal muscle ratio (%) | 25.5 ± 3.3 | 24.8 ± 3.2 | 25.8 ± 3.3 | 23.1 ± 2.5 | 24.7 ± 3.6 | 0.006 |
| Comorbidities | | | | | |
| Hypertension, n (%) | 9 (24.3) | 54 (24.1) | 6 (50.0) | 22 (48.9) | 22 (64.7) | < 0.001 |
| Diabetes, n (%) | 1 (2.7) | 10 (4.5) | 5 (41.7) | 6 (13.3) | 7 (20.6) | < 0.001 |
| Dyslipidemia, n (%) | 8 (21.6) | 73 (32.6) | 7 (58.3) | 21 (46.7) | 21 (61.8) | < 0.001 |
| RA disease characteristics | | | | | |
| Duration (year) | 11.1 ± 7.8 | 10.6 ± 10.0 | 11.0 ± 8.7 | 11.9 ± 10.1 | 8.9 ± 7.3 | 0.746 |
| HAQ score | 0.66 ± 0.62 | 0.46 ± 0.56 | 0.69 ± 0.69 | 0.48 ± 0.59 | 0.51 ± 0.60 | 0.256 |
| CRP (mg/dL) | 0.66 ± 1.81 | 0.35 ± 0.83 | 0.33 ± 0.38 | 0.26 ± 0.33 | 0.38 ± 0.56 | 0.329 |
| DAS28-ESR | **3.24 ± 1.03** | 2.61 ± 0.91 | 2.84 ± 0.87 | 2.77 ± 1.02 | 2.23 ± 0.89 | 0.047 |
| Current RA therapeutics characteristics | | | | | |
| cs DMARD use, n (%) | 32 (86.4) | 196 (87.5) | 9 (75.0) | 37 (82.2) | 27 (79.4) | 0.416 |
| ts DMARD use, n (%) | 0 (0) | 2 (0.9) | 0 (0) | 0 (0) | 0 (0) | 1.000 |
| Biological agent use, n (%) | 21 (56.8) | 115 (51.3) | 6 (50.0) | 22 (48.9) | 19 (55.9) | 0.945 |
| Prednisolone use, n (%) | 9 (24.3) | 37 (16.5) | 4 (33.3) | 14 (31.1) | 10 (29.4) | 0.061 |

Data are expressed as mean ± SD, or number (percentage)

BMI Body Mass Index, VFA visceral fat area, IMT intima–media thickness, SAF subcutaneous fat, V/S visceral fat area/subcutaneous fat area, HAQ Health Assessment Questionnaire, CRP C-reactive protein, DAS28-ESR Disease Activity Score in 28 joints using erythrocyte sedimentation rate, csDMARD conventional synthetic disease modifying anti-rheumatic drugs, ts DMARD targeted synthetic DMARD

*Analysis of variance for continuous variables or Fisher’s exact test for categorical variables

†‡§|| p < 0.05 for pairwise comparison with all other groups (multiple comparisons using Steel–Dwass)

¥ p < 0.05 for pairwise comparison with the group of Obesity (−) Visceral adiposity (−) and Obesity (+) Visceral adiposity (−), p = 0.001, p = 0.001, respectively (multiple comparisons using Steel–Dwass)

**p < 0.05 for pairwise comparison with the group of Obesity (−) Visceral adiposity (−) and Obesity (+) Visceral adiposity (+), p = 0.045, p = 0.007, respectively (multiple comparisons using Steel–Dwass)
Acknowledgements The authors would like to thank Ms. Sumie Naka-
gawa for management of blood specimens, Ms. Noriko Kitayama and
Ms. Maki Yoneyama for the fine support for the patients. We also thank
Editage (http://www.editage.jp) for English language editing.

Author contributions TY, MH, and KN: conception and design and
analysis and interpretation of the data, statistical analysis, and manu-
script preparation. RK and HY: obtained ultrasonography data. MT and
HI: obtained RA data. IM: obtained healthy control group data. KH:
conception and design and analysis and interpretation of the data. WY:
data management. RU and SM: statistical analysis. YF: conception and
design and interpretation of the data. TM: supervised the study.

Funding None.

Compliance with ethical standards

Ethical statement Masao Tanaka and Motomu Hashimoto are affili-
ated with the department that is financially supported by four phar-
macological companies (Mitsubishi-Tanabe, Chugai, Ayumi, and UC
Japan) and a city government (Nagahama city). Masao Tanaka has
received research grants from Actelion, Astellas, Asahi-Kasei Pharma,
Ayumi, Chugai, Daiichi Sankyo, Eisai, JB, Mitsubishi-Tanabe, MSD,
Nippon Shinyaku, Pfizer, Sanofi, and Takeda, and has participated in
speakers’ bureaus for Astellas, Bristol-Myers Squibb, Chugai, and
Mitsubishi-Tanabe. Kiminori Hosoda has received research Grants from
Omorpn Health Care Co., Ltd.

Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creativeco-
mmons.org/licenses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate
credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.

References

1. Kim YJ, Shim JS, Choi CB, Bea SC (2012) Mortality and inci-
dence of malignancy in Korean patients with rheumatoid arthritis.
J Rheumatol 39:226–232
2. Radovits BJ, Fransen J, Al Shamma S, Eijsbouts AM, van Riel
PLCM, Laan RFJM (2010) Excess mortality emerges after 10 years
in an inception cohort of early rheumatoid arthritis. Arthritis Care Res
(Hoboken) 62:362–370
3. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile
JM, Lacaille D (2008) Risk of cardiovascular mortality in patients
with rheumatoid arthritis: a meta-analysis of observational studies.
Arthritis Rheumat 59:1690–1697
4. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl
LA, Manson JE, Stampfer MJ, Curhan GC (2003) Cardiovas-
cular morbidity and mortality in women diagnosed with rheu-
matoid arthritis. Circulation 107:1303–1307
5. Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton
S, Dixo J. Early Rheumatoid Arthritis Study (ERAS) Group
(2007) Mortality in rheumatoid arthritis. Increased in the early
course of disease, in ischaemic heart disease and in pulmonary
fibrosis. Rheumatology (Oxford) 46:350–357
6. Mason JC, Libby P (2015) Cardiovascular disease in patients
with chronic inflammation: mechanisms underlying premature
vascular events in rheumatologic disorders. Eur Heart J 36:482–489c
7. Twig G, Yaniv G, Levine H, Leiba A, Goldberg N, Derazze E,
Ben-Ami Shor D, Tzur D, Afek A, Shamiss A, Haklai Z, Kark JD
(2016) Body Mass Index in 2.3 million adolescents and cardio-
vacular death in adulthood. N Engl J Med 374:2430–2440
8. Kremers HM, Nicola PJ, Crowson CS, Therenue TM, Roger VL,
Gabriel SE (2004) Prognostic importance of low Body Mass
Index in relation to cardiovascular mortality in rheumatoid arthri-
tis. Arthritis Rheumatol 50:3450–3457
9. Kremers HM, Crowson CS, Therenue TM, Roger VL, Gabriel SE
(2008) High ten-year risk of cardiovascular disease in newly
diagnosed rheumatoid arthritis patients: a population-based cohort
study. Arthritis Rheumatol 58:2268–2274
10. Walsmith J, Roubenoff R (2002) Cachexia in rheumatoid arthritis.
Int J Cardiol 85:89–99
11. Engvall IL, Elkan AC, Tengstrand B, Cederholm T, Brismar K,
Hafstrom I (2008) Cachexia in rheumatoid arthritis is associated
with inflammatory activity, physical disability, and low bioavail-
able insulin-like growth factor. Scand J Rheumatol 37:321–328
12. Elkan AC (2008) Malnutrition in women with rheumatoid arthri-
tis is not revealed by clinical anthropometrical measurements or
nutritional evaluation tools. Eur J Clin Nutr 62:1239–1247
13. Summers GD, Metsios GS, Stavropoulous-Kalinoglou A, Kitas GD
(2010) Rheumatoid cachexia and cardiovascular disease. Nat Rev
Rheumatol 6:445–451
14. Britton KA, Massaro JM, Murabito JM, Kreger BE, Hoffmann
U, Fox CS (2013) Body fat distribution, incident cardiovascular
disease, cancer, and all-cause mortality. J Am Coll Cardiol 62:921–925
15. Fujimoto WY, Bergstrom RW, Boyko EJ, Chen KW, Leonetti DL,
Newell-Morris L, Shoffer JB, Wahl PW (1999) Visceral adiposity
and incident coronary heart disease in Japanese-American men.
The 10-year follow-up results of the Seattle Japanese-American
Community Diabetes Study. Diabetes Care 22:1808–1812
16. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M (2007)
Prediction of clinical cardiovascular events with carotid intima-
media thickness: a systematic review and meta-analysis. Circula-
tion 115:459–467
17. Stein JH, Kocarcz CE, Hurst RT, Lonn E, Kendall CB, Mohler
ER et al (2008) Use of carotid ultrasound to identify subclinical
vascular disease and evaluate cardiac disease risk: a consen-
sus statement from the American Society of Echocardiogra-
phy Carotid Intima-Media Thickness Task Force. Endorsed by the
Society for Vascular Medicine. J Am Soc Echocardiogr 21:93–111
quiz 89–90.
18. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bing-
ham CO III et al (2010) Rheumatoid arthritis classification cri-
teria: an American College of Rheumatology/European League
Against Rheumatism collaborative initiative. Arthritis Rheumatol
62:2569–2581
19. Yanase T, Nasu S, Mukuta Y, Shimizu N, Nishihara T, Okabe T,
Nomura M, Inoguchi T, Nawata H (2006) Evaluation of a new carotid
intima-media thickness measurement by B-mode ultrasound
against rheumatoid arthritis: an American College of Rheumatology/European
League Against Rheumatism collaborative initiative. Arthritis Rheumatol
62:2569–2581
20. Terminology and Diagnostic Criteria Committee, Japan Society
Against Rheumatism collaborative initiative. Japan Society
of Ultrasonics in Medicine (2001) Standard method for ultrasound
evaluation of carotid artery lesions. J Med Ultrason 36:219–226
21. Oshima Y, Shiga T, Namba H, Kuno S (2010) Estimation of
whole-body skeletal muscle mass by bioelectrical impedance
analysis in the standing position. Obes Res Clin Pract 4:e1–e82
22. Shiga T, Hamaguchi T, Oshima Y, Kanai H, Hirata M, Hosoda
K et al (2009) A new simple measurement system of visceral fat

 Springer
23. Examination Committee of Criteria for ‘Obesity Disease’ in Japan; Japan Society for the Study of Obesity (2002) New criteria for ‘obesity disease’ in Japan. Circulation 66:987–992
24. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35:1381–1395
25. Giles JT (2010) Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheumatol 62:3173–3182
26. Inaba M (2007) Independent association of increased trunk fat with increased arterial stiffening in postmenopausal patients with rheumatoid arthritis. J Rheumatol 34:290–295
27. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444:860–867
28. Matsuza Y, Funahashi T, Nakamura T (2011) The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb 18:629–639
29. Muscaritoli M (2010) Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia–anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr 29:154–159
30. Roubenoff R (2004) Sarcopenic obesity: the confluence of two epidemics. Obes Res 12:887–888
31. Schrager MA (2007) Sarcopenic obesity and inflammation in the InCHIANTI study. J Appl Physiol 102:919–925
32. Baker JF, Cannon GW, Ibrahim S, Harolden C, Caplan L, Mikuls TR (2015) Predictors of long term changes in Body Mass Index in rheumatoid arthritis. J Rheumatol 42:920–927
33. Peters MJ, Symmons DP, McCoy D, Dijkmans BA, Nicola P, Kvienn TK et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331
34. Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ et al (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 76:17–28

Affiliations

Tamami Yoshida1 · Motomu Hashimoto2 · Rie Kawahara1 · Hiroko Yamamoto1 · Masao Tanaka2 · Hiromu Ito3 · Izuru Masuda4 · Kiminori Hosoda5 · Wataru Yamamoto2 · Ryuji Uozumi6 · Satoshi Morita6 · Yasutomo Fujii1 · Tsuneyo Mimori7 · Kazuko Nin1

Tamami Yoshida
yoshida.tamami.28v@kyoto-u.jp
Motomu Hashimoto
mohashim@kuhp.kyoto-u.ac.jp
Rie Kawahara
ahik428@yahoo.co.jp
Hiroko Yamamoto
yamamoto.hiroko.73x@st.kyoto-u.ac.jp
Masao Tanaka
masatana@kuhp.kyoto-u.ac.jp
Hiromu Ito
hiromu@kuhp.kyoto-u.ac.jp
Izuru Masuda
imasuda@kuhp.kyoto-u.ac.jp
Kiminori Hosoda
kiminorihosoda@ncvc.go.jp
Wataru Yamamoto
wyamamoto@wakokai.com
Ryuji Uozumi
uozumi@kuhp.kyoto-u.ac.jp
Satoshi Morita
smorita@kuhp.kyoto-u.ac.jp

Yasutomo Fujii
fujii.yasutomo.6c@kyoto-u.ac.jp
Tsuneyo Mimori
mimorit@kuhp.kyoto-u.ac.jp
1 Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
2 Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
3 Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
4 Medical Examination Center, Takeda Hospital, Kyoto, Japan
5 Department of Lifestyle-Related Disease, National Cerebral and Cardiovascular Center, Osaka, Japan
6 Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine Kyoto University, Kyoto, Japan
7 Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan